Provided by Tiger Trade Technology Pte. Ltd.

CRISPR Therapeutics AG

55.44
+0.12000.22%
Post-market: 55.40-0.0400-0.07%18:58 EDT
Volume:1.06M
Turnover:58.95M
Market Cap:5.36B
PE:-11.65
High:56.59
Open:55.45
Low:54.82
Close:55.32
52wk High:78.48
52wk Low:44.12
Shares:96.69M
Float Shares:93.17M
Volume Ratio:0.80
T/O Rate:1.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.7595
EPS(LYR):-6.4700
ROE:-26.09%
ROA:-14.20%
PB:3.07
PE(LYR):-8.57

Loading ...

ToolGen Raises KRW 19.5 Billion to Fund CRISPR Patent Battles and R&D

TIPRANKS
·
Sep 28

Snowflake, Palo Alto, Dell, GameStop, Crispr Insider Shock

TIPRANKS
·
Sep 26

Crispr Therapeutics General Counsel James R. Kasinger Disposes of Common Shares Worth $626,459.6

Reuters
·
Sep 25

Editas slips amid pressure on gene-editing sector after Anthropic update

TIPRANKS
·
Sep 24

Claude discovers novel enzyme system with CRISPR-like repeats

TIPRANKS
·
Sep 24

Crispr Therapeutics Director Ali Behbahani Disposes of Common Shares Worth $780,649.24

Reuters
·
Sep 22

Danaher’s IDT, Aldevron launch research grade S.p. Cas9 mRNA, SpyFi

TIPRANKS
·
Sep 16

CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewswire
·
Sep 08

Arm's Haas: AI Could Cure Cancer In Our Lifetime — If The Industry Can Build Enough Chips

AI Industry Frontlines
·
Sep 08

CRISPR Therapeutics (CRSP) Extends CTX310 Durability, Is The Stock Still Cheap?

Simply Wall St.
·
Sep 03

Investors Shrug Off Good News for Heart Patients from New Meds

Dow Jones
·
Sep 02

CRISPR Therapeutics (CRSP) Stock May Look Rich Following Fresh CTX310 Data

Simply Wall St.
·
Aug 30

Crispr Therapeutics AG (CRSP) Gets a Buy from William Blair

TIPRANKS
·
Aug 29

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

GlobeNewswire
·
Aug 28

Oculis Q2 Net Loss Narrows Despite Higher Expenses

Reuters
·
Aug 07

CRISPR Therapeutics AG (NASDAQ:CRSP) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Simply Wall St.
·
Aug 06

Goldman Sachs Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Aug 06

Intellia Therapeutics Q2 Collaboration Revenue Falls, Net Loss Widens

Reuters
·
Aug 06

RBC Capital Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Aug 06

Editas Medicine Q2 Net Loss Narrows and Beats Estimates

Reuters
·
Aug 06